LinQURE: A novel AAV gene silencing platform that supports multi-transcript targeting for complex disorders

Area of Science:

• Molecular Biology
• Gene Therapy
• Biotechnology

Background:

• Recombinant adeno-associated virus (rAAV)-delivered gene therapies offer potential for numerous genetic disorders.
• Targeting toxic transcripts with microRNA (miRNA)-based miQURE technology can reduce genetic disease progression.
• Complex genetic diseases involve multiple genes, necessitating multi-targeting therapeutic strategies.

Purpose of the Study:

• To establish a proof of mechanism for the novel linQURE platform.
• To demonstrate the ability of linQURE to enable concomitant expression of multiple synthetic miRNAs.
• To show efficient downregulation of disease-causing mRNA targets using the linQURE platform.

Main Methods:

• Expansion of the miQURE gene silencing strategy by concatenating multiple miQURE molecules into a single construct.
• Development of the linQURE platform for simultaneous miRNA expression.
• In vitro and in vivo validation of linQURE technology's efficacy.

Main Results:

• The linQURE platform successfully enabled the concomitant expression of two synthetic miRNAs.
• Demonstrated more efficient downregulation of disease-causing mRNA targets compared to single miRNA approaches.
• Validated the technology's effectiveness both in vitro and in vivo.

Conclusions:

• The linQURE platform represents a novel advancement in gene therapy, enabling multi-targeting strategies.
• This technology expands the potential of gene therapy to address complex multigenic indications.
• linQURE enhances the therapeutic toolbox for developing adaptable gene therapies for diverse genetic diseases.